SCHEDULE: BlackRock Amends Lexeo Therapeutics Stake to 4.0%
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.0% beneficial ownership stake in Lexeo Therapeutics, Inc. common stock.
Summary
- BlackRock, Inc. filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Lexeo Therapeutics, Inc. common stock.
- The filing indicates BlackRock, Inc. beneficially owns an aggregate of 2,168,444 shares of Lexeo Therapeutics, Inc. common stock.
- This aggregate amount represents 4.0% of the class of securities.
- BlackRock, Inc. holds sole voting power over 2,129,602 shares.
- BlackRock, Inc. holds sole dispositive power over 2,168,444 shares.
- No shared voting or dispositive power is reported.
- The filing was made under Rule 13d-1(b), indicating the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control.
- BlackRock, Inc.'s principal business office is located at 50 Hudson Yards, New York, NY 10001.
- Several BlackRock subsidiaries, including BlackRock Advisors, LLC and BlackRock Fund Advisors, are identified as relevant subsidiaries, though none individually beneficially own 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership by an institutional investor and does not contain information that would inherently suggest a positive or negative sentiment regarding the issuer's performance or prospects.
Industry Context
This filing is a standard disclosure of passive institutional ownership, reflecting BlackRock's investment in Lexeo Therapeutics, Inc. It does not provide specific insights into Lexeo's operational performance or broader industry trends, but rather BlackRock's portfolio allocation.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney date, which was expressly revoked by the new one. |
| 2025-01-21 | Date of execution for the new Power of Attorney by BlackRock, Inc. |
| 2025-09-30 | Date of event which required the filing of this statement. |
| 2025-10-17 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
Lexeo Therapeutics, BlackRock, Schedule 13G, Common Stock, Institutional Ownership, Beneficial Ownership, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.